Jump to content

Nitrofurantoin

From Wikipedia, the free encyclopedia

Nitrofurantoin
Structural formula of nitrofurantoin
Ball-and-stick model of the nitrofurantoin molecule
Clinical data
Trade namesMacrobid, others[1]
AHFS/Drugs.comMonograph
MedlinePlusa682291
License data
Pregnancy
category
Routes of
administration		By mouth[4]
Drug classAntibiotic
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability~20–94%[11][12][13]
Protein binding60–77% (primarily albumin)[14][13]
Elimination half-life0.33–1.7 hours[12][15][11][14][13]
ExcretionAlmost exclusively urine (4–59% over 3–30 hours; ~20–25% unchanged) and bile[12][15][11][4][14][13]
Identifiers
  • (E)-1-[(5-nitro-2-furyl)methylideneamino]imidazolidine-2,4-dione
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.587 Edit this at Wikidata
Chemical and physical data
FormulaC8H6N4O5
Molar mass238.159 g·mol−1
3D model (JSmol)
Melting point270 to 272 °C (518 to 522 °F) (decomp.)
  • O=[N+]([O-])c2oc(/C=N/N1C(=O)NC(=O)C1)cc2
  • InChI=1S/C8H6N4O5/c13-6-4-11(8(14)10-6)9-3-5-1-2-7(17-5)12(15)16/h1-3H,4H2,(H,10,13,14)/b9-3+ checkY
  • Key:NXFQHRVNIOXGAQ-YCRREMRBSA-N checkY
  (verify)

Nitrofurantoin, sold under the brand name Macrobid among others, is an antibacterial medication of the nitrofuran class used to treat urinary tract infections (UTIs), although it is not as effective for kidney infections.[16] It is taken by mouth.[16]

Common side effects include nausea, loss of appetite, diarrhea, and headaches.[16] Rarely numbness, lung problems, or liver problems may occur.[16] While it appears to be generally safe during pregnancy its use is not recommended near time of delivery.[16][2] While it usually works by slowing bacterial growth, it may result in bacterial death at the high concentrations found in urine, provided forced fluid dilution of urine is avoided.[16][failed verification]

Nitrofurantoin was first sold in 1953.[17] It is on the World Health Organization's List of Essential Medicines.[18] It is available as a generic medication.[16] In 2022, it was the 158th most commonly prescribed medication in the United States, with more than 3 million prescriptions.[19][20]

Medical uses

[edit]
100 mg Macrobid, Canada

Urinary tract infections

[edit]

Uses of nitrofurantoin include the treatment of uncomplicated urinary tract infections (UTIs) and prophylaxis against UTIs in people prone to recurrent UTIs.[9] It is a first-line therapy for acute uncomplicated cystitis.[21] It is not recommended for empiric treatment of hospital-acquired UTIs.[21]

Increasing bacterial antibiotic resistance to other commonly used agents, such as trimethoprim/sulfamethoxazole and fluoroquinolones, has led to increased interest in using nitrofurantoin in the contemporary treatment of UTIs.[22][23] The efficacy of nitrofurantoin in treating UTIs combined with a low rate of bacterial resistance to this agent makes it one of the first-line agents for treating uncomplicated UTIs as recommended by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.[24]

In meta-analyses of clinical trials, nitrofurantoin has shown clinical UTI cure rates of 79 to 92% and bacterial eradication rates of 80 to 92%.[15][25] Treatment with nitrofurantoin for 7 days was not more effective than treatment for 5 days, whereas treatment for 5 days was superior to treatment for 3 days (which showed clinical cure rates of 61–70%).[15][25][21] The effectiveness of nitrofurantoin for 5 days is equivalent to that with single-dose fosfomycin.[26]

As a prophylactic against UTIs, nitrofurantoin was similarly effective to other antibiotics, with a UTI risk ratio of 0.38.[27][28] Taken daily long-term as a prophylactic, there were no differences in effectiveness between different doses of nitrofurantoin (50 mg/day, 75 mg/day, 100 mg/day, or 50 mg twice daily).[27] Although similarly effective as other antibiotics, prophylactic nitrofurantoin showed an increased risk of adverse effects compared to other antibiotics (risk ratios = 2.17 to 2.24).[27][28] The adverse effects of nitrofurantoin were mostly gastrointestinal in nature.[28]

Other bacterial infections

[edit]

Nitrofurantoin is not recommended for the treatment of pyelonephritis (kidney infection),[24] and intra-abdominal abscess,[29] because of extremely poor tissue penetration and low blood levels.[16][21]

Nitrofurantoin appears likely to minimally penetrate the prostate gland.[30][31][32] As such, nitrofurantoin is not recommended for eradication of chronic bacterial prostatitis.[33] In any case, in men with antibiotic-refractory or relapsing chronic bacterial prostatitis, prophylactic nitrofurantoin may be useful in preventing UTIs and managing symptoms.[30][34][35] However, supporting data are lacking as of 2020.[30]

Antibacterial activity

[edit]

Nitrofurantoin has been shown to have good activity against:[36][21]

It is used in the treatment of infections caused by these organisms.[37]

Many or all strains of the following genera are resistant to nitrofurantoin:[37][36]

Special populations

[edit]

Pregnancy

[edit]

Nitrofurantoin is pregnancy category A in Australia.[3] It is one of the few drugs commonly used in pregnancy to treat UTIs.[38] There is a potential risk of hemolytic anemia in the newborn when used near time of delivery.[3] Newborns of women given this drug late in pregnancy had a higher risk of developing neonatal jaundice.[39]

Evidence of safety in early pregnancy is mixed as of 2017.[40] The American College of Obstetricians and Gynecologists states that while they can be used in the first trimester other options may be preferred.[40] They remain a first line treatment in the second trimester.[40] A 2015 meta analysis found no increased risk from first trimester use in cohort studies that was a slight increase of malformations in case control studies.[41]

Contraindications

[edit]

Nitrofurantoin is contraindicated in patients with decreased renal function (CrCl < 60 ml/min) due to systemic accumulation and subtherapeutic levels reached in the urinary tract.[9] However, a retrospective chart review suggests the data for this cutoff are slim and a cutoff of CrCl < 40 ml/min would be more appropriate.[42] Many of the severe side effects of this drug are more common in the elderly and those with renal impairment, as this causes the drug to be retained in the body and reach higher systemic levels. Thus, the drug is not recommended for the elderly population according to 2012 AGS Beers Criteria.[43]

Nitrofurantoin is also contraindicated in babies up to the age of one month, as they have immature enzyme systems in their red blood cells (glutathione instability), so nitrofurantoin must not be used because it can cause haemolytic anaemia. Nitrofurantoin is contraindicated in patients with glucose-6-phosphate dehydrogenase deficiency (G6PD) because of risk of intravascular hemolysis resulting in anemia.[9]

Adverse effects

[edit]

The most common side effects of nitrofurantoin are nausea, headache, and flatulence. Less common adverse events (occurring in less than 1% of those taking the drug) include:[9]

  • Gastrointestinal: diarrhea, dyspepsia, abdominal pain, constipation, emesis
  • Neurologic: dizziness, drowsiness, amblyopia
  • Respiratory: acute pulmonary hypersensitivity reaction
  • Allergic: pruritus, urticaria
  • Dermatologic: hair loss
  • Miscellaneous: fever, chills, malaise

Taken daily long-term as a prophylactic, side effects of nitrofurantoin occur at rates of 0 to 29%.[28] They are generally mild, reversible, and are predominantly gastrointestinal.[28]

Lung toxicity

[edit]

The pulmonary toxicity caused by nitrofurantoin can be categorized into acute, subacute, and chronic pulmonary reactions. The acute and subacute reactions are thought to be due to a hypersensitivity reaction and often resolve when the drug is discontinued. Acute reactions have been estimated to occur in about one in 5000 women who take the drug.[44][45] These reactions usually develop 3–8 days after the first dose of nitrofurantoin, but may occur from a few hours to a few weeks after starting the drug. Symptoms include fever, dyspnea, chills, cough, pleuritic chest pain, headache, back pain, and epigastric pain. Chest radiograph will often show unilateral or bilateral infiltrates similar to pulmonary edema.[46]

Chronic pulmonary reactions caused by nitrofurantoin include diffuse interstitial pneumonitis, pulmonary fibrosis, or both.[9] This uncommon reaction may occur 1 month to 6 years after starting the drug and is usually related to its total lifetime dose.[citation needed] This reaction manifests with progressive shortness of breath.[47] It is important to recognize nitrofurantoin as possible cause of symptoms and discontinue the drug when the suspicion of pulmonary side effects arises as it can be reversible if the drug is stopped early.[45]

Liver toxicity

[edit]

Liver reactions, including hepatitis, cholestatic jaundice, chronic active hepatitis, and hepatic necrosis, occur rarely.[48]

Neuropathy

[edit]

Neuropathy is a rare side effect of taking nitrofurantoin. Patients may experience numbness and tingling in a stocking-glove pattern, which may or may not improve upon discontinuation of the drug.[49]

Gut microflora

[edit]

Nitrofurantoin has been found to modify the gut microbiota composition.[50] Effects in three clinical studies have included increased abundance of Actinobacteria, Bifidobacterium species, and Clostridium species, decreased abundance of Faecalibacterium species, and no changes.[50] Similarly to other antibiotics, nitrofurantoin has been associated with increased risk of Clostridioides difficile infection and associated diarrhea.[51][52] However, this was based on a single study in which only two cases occurred.[51][52] Other sources state that nitrofurantoin has a low risk of Clostridioides difficile infection.[21]

Interactions

[edit]

Nitrofurantoin has historically been reported to be a disulfiram-like drug and to produce alcohol intolerance-type reactions when combined with alcohol.[53] However, subsequent clinical studies failed to replicate these findings and the earlier results have been deemed erroneous.[53]

Pharmacology

[edit]

Organisms are said to be susceptible to nitrofurantoin if their minimum inhibitory concentration is 32 μg/mL or less. The peak blood concentration of nitrofurantoin following an oral dose of nitrofurantoin 100 mg is less than 1 μg/mL and may be undetectable. Its bioavailability is about 90% and the urinary excretion is 40%[14] tissue penetration is negligible; the drug is well concentrated in the urine: 75% of the dose is rapidly metabolised by the liver, but 25% of the dose is excreted in the urine unchanged, reliably achieving levels of 200 μg/mL or more. In studies of dogs, the majority of urinary excretion is through glomerular filtration with some tubular secretion.[54] There is also tubular absorption which is increased with urine acidification.[54] However the activity of nitrofurantoin is also pH dependent and mean inhibitory concentration rises sharply with increased pH above 6.[54] Nitrofurantoin cannot be used to treat infections other than simple cystitis.

At the concentrations achieved in urine (>100 μg/mL), nitrofurantoin is a bactericide. It is bacteriostatic against most susceptible organisms at concentrations less than 32 μg/mL.[9]

Nitrofurantoin and the quinolone antibiotics are mutually antagonistic in vitro. It is not known whether this is of clinical significance.[9]

Resistance to nitrofurantoin may be chromosomal or plasmid-mediated and involves inhibition of nitrofuran reductase.[55] Acquired resistance in E. coli continues to be rare.

Nitrofurantoin and its metabolites are excreted mainly by the kidneys. In renal impairment, the concentration achieved in urine may be subtherapeutic.[56]

Mechanism of action

[edit]

Nitrofurantoin is concentrated in the urine, leading to higher and more effective levels in the urinary tract than in other tissues or compartments.[45] With a 100 mg oral dose, plasma levels are typically less than 1 μg/mL while in the urine it reaches 200 μg/mL.[57]

The drug works by damaging bacterial DNA, since its reduced form is highly reactive.[9] This is made possible by the rapid reduction of nitrofurantoin inside the bacterial cell by flavoproteins (nitrofuran reductase) to multiple reactive intermediates that attack ribosomal proteins, DNA,[58] respiration, pyruvate metabolism and other macromolecules within the cell. Nitrofurantoin exerts greater effects on bacterial cells than mammalian cells because bacterial cells activate the drug more rapidly. It is not known which of the actions of nitrofurantoin is primarily responsible for its bactericidal activity. The broad mechanism of action for nitrofurantoin is likely responsible for the low development of resistance to its effects, as it affects many different processes important to the bacterial cell.[9]

History

[edit]

Nitrofurantoin has been available for the treatment of lower UTIs since 1953.[17]

Society and culture

[edit]

Brand names

[edit]

Nitrofurantoin is marketed under many names in countries worldwide.[59]

Animal feed

[edit]

Residues from the breakdown of nitrofuran veterinary antibiotics, including nitrofurantoin, have been found in chicken in Vietnam, China, Brazil, and Thailand.[60] The European Union prohibited the use of nitrofurans in food producing animals by classifying it in ANNEX IV (list of pharmacologically active substances for which no maximum residue limits can be fixed) of the Council Regulation 2377/90. The Food and Drug Administration (FDA) of the United States has prohibited furaltadone since February 1985 and withdrew the approval for the other nitrofuran drugs (except some topical uses) in January 1992. The topical use of furazolidone and nitrofurazone was prohibited in 2002. Australia prohibited the use of nitrofurans in food production in 1992. Japan did not allocate MRLs for nitrofurans leading to the implementation of a "zero tolerance or no residue standard". In Thailand, the Ministry of Health issued in 2001 Proclamation No. 231 MRL of veterinary drug in food which did not allocate MRL for nitrofurans. The Ministry of Agriculture and Cooperatives had already prohibited importation and use of furazolidone and nitrofurazone in animal feed in 1999 which was extended to all nitrofurans in 2002. Several metabolites of nitrofurans, such as furazolidone, furaltadone and nitrofurazone cause cancer or genetic damage in rats.[60]

References

[edit]
  1. ^ "Nitrofurantoin".
  2. ^ a b "Prescribing medicines in pregnancy database". Australian Government. 3 March 2014. Archived from the original on 8 April 2014. Retrieved 22 April 2014.
  3. ^ a b c "Nitrofurantoin Use During Pregnancy". Drugs.com. Archived from the original on 3 December 2018. Retrieved 10 September 2019.
  4. ^ a b https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020064Orig1s029lbl.pdf
  5. ^ "Macrodantin Product Information". TGA eBS. 24 June 2024. Retrieved 24 June 2024.
  6. ^ "Macrodantin Product information". Health Canada. 16 September 1996. Retrieved 24 June 2024.
  7. ^ "Macrobid Product information". Health Canada. 12 August 2021. Retrieved 24 June 2024.
  8. ^ "Macrobid Summary of Product Characteristics (SmPC)". (emc). 14 February 2024. Retrieved 24 June 2024.
  9. ^ a b c d e f g h i j "Macrobid - nitrofurantoin monohydrate/macrocrystalline capsule". DailyMed. 30 June 2023. Retrieved 24 June 2024.
  10. ^ https://www.ema.europa.eu/en/documents/psusa/nitrofurantoin-nifurtoinol-list-nationally-authorised-medicinal-products-psusa00002174202102_en.pdf [bare URL PDF]
  11. ^ a b c Wijma RA, Fransen F, Muller AE, Mouton JW (March 2019). "Optimizing dosing of nitrofurantoin from a PK/PD point of view: What do we need to know?". Drug Resist Updat. 43: 1–9. doi:10.1016/j.drup.2019.03.001. PMID 30947111.
  12. ^ a b c Cunha BA (July 1988). "Nitrofurantoin--current concepts". Urology. 32 (1): 67–71. doi:10.1016/0090-4295(88)90460-8. PMID 3291373.
  13. ^ a b c d Dos Santos C, Dos Santos LS, Franco OL (September 2021). "Fosfomycin and nitrofurantoin: classic antibiotics and perspectives". J Antibiot (Tokyo). 74 (9): 547–558. doi:10.1038/s41429-021-00444-z. PMID 34244614.
  14. ^ a b c d Conklin JD (1978). "The pharmacokinetics of nitrofurantoin and its related bioavailability". Pharmacokinetics. Antibiotics and Chemotherapy. Vol. 25. pp. 233–252. doi:10.1159/000401065. ISBN 978-3-8055-2752-1. PMID 352255.
  15. ^ a b c d Wijma RA, Huttner A, Koch BC, Mouton JW, Muller AE (November 2018). "Review of the pharmacokinetic properties of nitrofurantoin and nitroxoline". Journal of Antimicrobial Chemotherapy. 73 (11): 2916–2926. doi:10.1093/jac/dky255. PMID 30184207.
  16. ^ a b c d e f g h "Nitrofurantoin". The American Society of Health-System Pharmacists. Archived from the original on 7 July 2015. Retrieved 1 August 2015.
  17. ^ a b Blass B (2015). Basic Principles of Drug Discovery and Development. Elsevier. p. 511. ISBN 9780124115255. Archived from the original on 8 September 2017.
  18. ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  19. ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  20. ^ "Nitrofurantoin Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
  21. ^ a b c d e f g h i j k l m n o p q Bader MS, Loeb M, Leto D, Brooks AA (April 2020). "Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents". Postgrad Med. 132 (3): 234–250. doi:10.1080/00325481.2019.1680052. PMID 31608743.
  22. ^ Garau J (January 2008). "Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline". Clinical Microbiology and Infection. 14 (Suppl 1): 198–202. doi:10.1111/j.1469-0691.2007.01852.x. PMID 18154548.
  23. ^ McKinnell JA, Stollenwerk NS, Jung CW, Miller LG (June 2011). "Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis". Mayo Clinic Proceedings. 86 (6): 480–488. doi:10.4065/mcp.2010.0800. PMC 3104907. PMID 21576512.
  24. ^ a b Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. (March 2011). "International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases". Clinical Infectious Diseases. 52 (5): e103–e120. doi:10.1093/cid/ciq257. PMID 21292654.
  25. ^ a b Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW (September 2015). "Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials". J Antimicrob Chemother. 70 (9): 2456–2464. doi:10.1093/jac/dkv147. PMID 26066581.
  26. ^ Konwar M, Gogtay NJ, Ravi R, Thatte UM, Bose D (May 2022). "Evaluation of efficacy and safety of fosfomycin versus nitrofurantoin for the treatment of uncomplicated lower urinary tract infection (UTI) in women - A systematic review and meta-analysis". J Chemother. 34 (3): 139–148. doi:10.1080/1120009X.2021.1938949. PMID 34151754.
  27. ^ a b c Muller AE, Verhaegh EM, Harbarth S, Mouton JW, Huttner A (June 2017). "Nitrofurantoin's efficacy and safety as prophylaxis for urinary tract infections: a systematic review of the literature and meta-analysis of controlled trials". Clin Microbiol Infect. 23 (6): 355–362. doi:10.1016/j.cmi.2016.08.003. PMID 27542332.
  28. ^ a b c d e Price JR, Guran LA, Gregory WT, McDonagh MS (November 2016). "Nitrofurantoin vs other prophylactic agents in reducing recurrent urinary tract infections in adult women: a systematic review and meta-analysis". Am J Obstet Gynecol. 215 (5): 548–560. doi:10.1016/j.ajog.2016.07.040. PMID 27457111.
  29. ^ Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. (January 2010). "Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America". Clinical Infectious Diseases. 50 (2): 133–164. doi:10.1086/649554. PMID 20034345.
  30. ^ a b c Su ZT, Zenilman JM, Sfanos KS, Herati AS (June 2020). "Management of Chronic Bacterial Prostatitis". Curr Urol Rep. 21 (7): 29. doi:10.1007/s11934-020-00978-z. PMID 32488742.
  31. ^ Lipsky BA, Byren I, Hoey CT (June 2010). "Treatment of bacterial prostatitis". Clin Infect Dis. 50 (12): 1641–1652. doi:10.1086/652861. PMID 20459324. Nitrofurantoin prostatic levels are likely nontherapeutic.
  32. ^ Charalabopoulos K, Karachalios G, Baltogiannis D, Charalabopoulos A, Giannakopoulos X, Sofikitis N (December 2003). "Penetration of antimicrobial agents into the prostate". Chemotherapy. 49 (6): 269–279. doi:10.1159/000074526. PMID 14671426. Good to excellent penetration into prostatic fluid and tissue has been demonstrated with many antimicrobial agents, including tobramycin, netilmicin, tetracyclines, macrolides, quinolones, sulfonamides and nitrofurantoin. [...] Nitrofurantoin is a lipid-soluble weak acid with a pKa value that is somewhat favorable for diffusion into prostatic fluid [78]. Although low levels of nitrofurantoin were achieved in prostatic fluid in dogs, the administration of standard oral doses of this drug to men results in levels of ≤1 μg/ml of blood; such levels guarantee that the levels attained in prostatic fluid will be nontherapeutic.
  33. ^ Chou A, Welch E, Hunter A, Trautner BW (March 2022). "Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review". Drugs. 82 (4): 407–438. doi:10.1007/s40265-022-01676-5. PMC 9057390. PMID 35286622. We agree with guidelines [270] recommending fluoroquinolones, trimethoprim, and tetracyclines for treatment of chronic bacterial prostatitis, if the causative organism is susceptible. Emerging pharmacologic and clinical data also support the use of oral fosfomycin 3g every 2 days for 6–12 weeks for treatment of chronic bacterial prostatitis [256, 266, 271]. We avoid prescribing nitrofurantoin due to concerns of poor prostatic concentration [265].
  34. ^ Bowen DK, Dielubanza E, Schaeffer AJ (August 2015). "Chronic bacterial prostatitis and chronic pelvic pain syndrome". BMJ Clin Evid. 2015. PMC 4551133. PMID 26313612. A third-line option is chronic oral antibiotic suppression to prevent recurrent cystitis. There is the potential for side effects with any medication, thus the risks of chronic antibiotic use (such as tendon damage with quinolones) must be weighed against the potential benefits. However, a chronic suppression approach only mandates adequate drug levels in the urine and does not require penetrance of the prostate, thus many antibiotic choices with a safer side effect profile are available, such as nitrofurantoin and cephalosporins.
  35. ^ Fowler JE (December 2002). "Antimicrobial therapy for bacterial and nonbacterial prostatitis". Urology. 60 (6 Suppl): 24–6, discussion 26. doi:10.1016/s0090-4295(02)02300-2. PMID 12521585. The fluoroquinolone antibiotics given for 2 to 4 weeks will cure about 70% of chronic bacterial infections of the prostate. If this treatment fails, the symptomatic manifestations of the infections can almost always be eliminated with suppressive antimicrobial therapy using [...] nitrofurantoin. [...] Reported experiences with chronic bacterial prostatitis indicate that low-dose [...] nitrofurantoin (50 or 100 mg once daily) are remarkably effective.1,8 A large experience with these agents for prophylaxis against frequent urinary tract reinfection in women suggest that indefinite treatment is generally well tolerated.1 [...] Nitrofurantoin macrocrystals, 100 mg twice daily for 7 days is recommended for the initial treatment of suspected chronic bacterial prostatitis [...] Nitrofurantoin macrocrystals will not eradicate bacteria in the prostate and will facilitate the interpretation of subsequent lower tract bacterial localization studies.9
  36. ^ a b c d e f g h i j k l m Mahdizade Ari M, Dashtbin S, Ghasemi F, Shahroodian S, Kiani P, Bafandeh E, et al. (2023). "Nitrofurantoin: properties and potential in treatment of urinary tract infection: a narrative review". Front Cell Infect Microbiol. 13: 1148603. doi:10.3389/fcimb.2023.1148603. PMC 10414118. PMID 37577377.
  37. ^ a b Gupta K, Scholes D, Stamm WE (February 1999). "Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women". JAMA. 281 (8): 736–738. doi:10.1001/jama.281.8.736. PMID 10052444.
  38. ^ Lee M, Bozzo P, Einarson A, Koren G (June 2008). "Urinary tract infections in pregnancy". Canadian Family Physician. 54 (6): 853–854. PMC 2426978. PMID 18556490. Archived from the original on 28 August 2021. Retrieved 4 August 2009.
  39. ^ Nordeng H, Lupattelli A, Romøren M, Koren G (February 2013). "Neonatal outcomes after gestational exposure to nitrofurantoin". Obstetrics and Gynecology. 121 (2 Pt 1): 306–313. doi:10.1097/AOG.0b013e31827c5f88. PMID 23344280. S2CID 25848306.
  40. ^ a b c "Sulfonamides, Nitrofurantoin, and Risk of Birth Defects - ACOG". www.acog.org. Archived from the original on 30 September 2019. Retrieved 25 November 2019.
  41. ^ Goldberg O, Moretti M, Levy A, Koren G (February 2015). "Exposure to nitrofurantoin during early pregnancy and congenital malformations: a systematic review and meta-analysis". Journal of Obstetrics and Gynaecology Canada. 37 (2): 150–156. doi:10.1016/S1701-2163(15)30337-6. PMID 25767948.
  42. ^ Oplinger M, Andrews CO (January 2013). "Nitrofurantoin contraindication in patients with a creatinine clearance below 60 mL/min: looking for the evidence". The Annals of Pharmacotherapy. 47 (1): 106–111. doi:10.1345/aph.1R352. PMID 23341159. S2CID 28181644.
  43. ^ American Geriatrics Society 2012 Beers Criteria Update Expert Panel (April 2012). "American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults". Journal of the American Geriatrics Society. 60 (4): 616–631. doi:10.1111/j.1532-5415.2012.03923.x. PMC 3571677. PMID 22376048.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  44. ^ Jick SS, Jick H, Walker AM, Hunter JR (September 1989). "Hospitalizations for pulmonary reactions following nitrofurantoin use". Chest. 96 (3): 512–515. doi:10.1378/chest.96.3.512. PMID 2766810.
  45. ^ a b c Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW (September 2015). "Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials". The Journal of Antimicrobial Chemotherapy. 70 (9): 2456–2464. doi:10.1093/jac/dkv147. PMID 26066581.
  46. ^ Williams EM, Triller DM (May 2006). "Recurrent acute nitrofurantoin-induced pulmonary toxicity". Pharmacotherapy. 26 (5): 713–718. doi:10.1592/phco.26.5.713. PMID 16718946. S2CID 29563196.
  47. ^ Goemaere NN, Grijm K, van Hal PT, den Bakker MA (May 2008). "Nitrofurantoin-induced pulmonary fibrosis: a case report". Journal of Medical Case Reports. 2 (1): 169. doi:10.1186/1752-1947-2-169. PMC 2408600. PMID 18495029.
  48. ^ Amit G, Cohen P, Ackerman Z (March 2002). "Nitrofurantoin-induced chronic active hepatitis". The Israel Medical Association Journal. 4 (3): 184–186. PMID 11908259.
  49. ^ Tan IL, Polydefkis MJ, Ebenezer GJ, Hauer P, McArthur JC (February 2012). "Peripheral nerve toxic effects of nitrofurantoin". Archives of Neurology. 69 (2): 265–268. doi:10.1001/archneurol.2011.1120. PMID 22332195.
  50. ^ a b Zimmermann P, Curtis N (December 2019). "The effect of antibiotics on the composition of the intestinal microbiota - a systematic review". J Infect. 79 (6): 471–489. doi:10.1016/j.jinf.2019.10.008. PMID 31629863.
  51. ^ a b Bignardi GE (September 1998). "Risk factors for Clostridium difficile infection". J Hosp Infect. 40 (1): 1–15. doi:10.1016/s0195-6701(98)90019-6. PMID 9777516.
  52. ^ a b Hirschhorn LR, Trnka Y, Onderdonk A, Lee ML, Platt R (January 1994). "Epidemiology of community-acquired Clostridium difficile-associated diarrhea". J Infect Dis. 169 (1): 127–133. doi:10.1093/infdis/169.1.127. PMID 8277174.
  53. ^ a b Mergenhagen KA, Wattengel BA, Skelly MK, Clark CM, Russo TA (February 2020). "Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions". Antimicrobial Agents and Chemotherapy. 64 (3). doi:10.1128/AAC.02167-19. PMC 7038249. PMID 31871085.
  54. ^ a b c Shah RR, Wade G (1989). "Reappraisal of the risk/benefit of nitrofurantoin: review of toxicity and efficacy". Adverse Drug Reactions and Acute Poisoning Reviews. 8 (4): 183–201. PMID 2694823.
  55. ^ McCalla DR, Kaiser C, Green MH (January 1978). "Genetics of nitrofurazone resistance in Escherichia coli". Journal of Bacteriology. 133 (1): 10–16. doi:10.1128/JB.133.1.10-16.1978. PMC 221970. PMID 338576.
  56. ^ Bains A, Buna D, Hoag NA (2009). "A retrospective review assessing the efficacy and safety of nitrofurantoin in renal impairment". Canadian Pharmacists Journal. 142 (5): 248–252. doi:10.3821/1913-701X-142.5.248. S2CID 56795699.
  57. ^ Blass B (24 April 2015). Basic Principles of Drug Discovery and Development. Elsevier. p. 513. ISBN 9780124115255.
  58. ^ Tu Y, McCalla DR (August 1975). "Effect of activated nitrofurans on DNA". Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis. 402 (2): 142–149. doi:10.1016/0005-2787(75)90032-5. PMID 1100114.
  59. ^ "Nitrofurantoin". drugs.com. Archived from the original on 18 May 2015. Retrieved 2 May 2015.
  60. ^ a b "Joint FAO/WHO Technical Workshop on Residues of Veterinary Drugs without ADI/MRL - Bangkok, 24 – 26 August 2004". www.fao.org. Archived from the original on 4 December 2008.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Nitrofurantoin&oldid=1256897901"